Serum lactate dehydrogenase (LDH) as a prognostic index for non-Hodgkin's lymphoma

Eur J Cancer Clin Oncol. 1982 Oct;18(10):945-9. doi: 10.1016/0277-5379(82)90242-5.

Abstract

According to pretreatment values of serum lactate dehydrogenase (LDH), 113 consecutive patients with non-Hodgkin's lymphoma were divided into three levels: level 1 (within normal range) with LDH less than 250 U/l; level 2 (moderately increased) with LDH between 250 and 500 U/l; level 3 (highly increased) with LDH more than 500 U/l. LDH was elevated in 46 of 113 patients (41%). Normal values of LDH were associated with a better response to therapy and a longer survival, independent of histological type and clinical stage, with one exception; in stage IV patients conclusions could not be drawn concerning the response to therapy (complete remission occurred only in 8 of 44). Even though level 2 patients behaved slightly better than level 3 patients, no statistical difference has been observed between the two levels. Accordingly, serum LDH can be considered a useful predictor of response to therapy and of survival in non-Hodgkin's lymphoma.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Female
  • Humans
  • L-Lactate Dehydrogenase / blood*
  • Lymphoma / drug therapy
  • Lymphoma / enzymology*
  • Lymphoma / mortality
  • Male
  • Middle Aged
  • Prognosis

Substances

  • L-Lactate Dehydrogenase